Docetaxel Micelles: A New Formulation to Diminish Hypersensitivity Reactions

Docetaxel Micelles: A New Formulation to Diminish Hypersensitivity Reactions

<b>Background/Objectives</b>: Docetaxel is a potent anti-cancer agent capable of treating various types of cancer. However, it often induces a range of adverse reactions when used with its standard solubilizer, Tween-80, necessitating allergy prophylaxis with dexamethasone prior to admin...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lanlan Xiang, Hao Wang, Jiajie Liu, Yuchen Shen, Yanfen Hu, Wenchen Che, Ran Li, Sisi Yang, Xin Teng
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Series:	Pharmaceutics
Subjects:	docetaxel nanomicelles allergic reaction
Online Access:	https://www.mdpi.com/1999-4923/17/2/184
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Engineering Docetaxel Micelles for Enhanced Cancer Therapy Through Intermolecular Forces
by: Hao Wang, et al.
Published: (2024-10-01)

Preparation and Characterization of Olmesartan Medoxomil-Loaded Polymeric Mixed Micelle Nanocarrier
by: Halah Talal Sulaiman, et al.
Published: (2025-02-01)

ANALYSIS OF ADVERSE DRUG REACTIONS (ADRs) AND THEIR SEVERITY IN BREAST CANCER PATIENTS TREATED WITH THE DOCETAXEL-DOXORUBICIN REGIMEN AT SULTAN AGUNG ISLAMIC HOSPITAL
by: Muh Maskur Setiaji, et al.
Published: (2025-07-01)

Enhanced penetration and biofilm eradication by sophorolipid micelles encapsulating Honokiol: a comprehensive solution for biofilm-associated lung infections
by: Shiyu Lin, et al.
Published: (2025-02-01)

Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients
by: Yongzhe Tang, et al.
Published: (2025-05-01)

Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer
by: Hejar Atalan, et al.
Published: (2025-06-01)

Effect of docetaxel administration on fluid dynamics in mice
by: Ayana Mawaki, et al.
Published: (2025-05-01)

Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients
by: Eva González-Haba-Peña, et al.
Published: (2020-09-01)

Metformin-Sensitized Chemotherapy of Docetaxel Nanoemulsions Based on a Sequential Administration
by: Junlei Zhang, et al.
Published: (2025-06-01)

Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
by: Aleymi M. Perez, et al.
Published: (2024-09-01)

Encapsulation nanoarchitectonics of glabridin with sophorolipid micelles for addressing biofilm hazards via extracellular polymeric substance permeation and srtA gene suppression
by: Shiyu Lin, et al.
Published: (2024-11-01)

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre‐clinical study
by: Kaan Low, et al.
Published: (2024-09-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Effect of Curcumin on Docetaxel-Induced Apoptosis in the DU145 (Prostate) Cell Line Using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay
by: Mohammad Shokrzadeh, et al.
Published: (2025-07-01)

Feasibility and Safety of Anlotinib Plus Docetaxel versus Docetaxel Monotherapy in Patients with Previously Immunotherapy-Treated NSCLC: A Retrospective Exploratory Study
by: Li DW, et al.
Published: (2025-04-01)

DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)

Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study
by: Thanutcha Mahathumnuchok, et al.
Published: (2025-08-01)

EFFECT OF CHEMOTHERAPY WITH DOCETAXEL / CISPLATIN ON GRANULOCYTIC HEMOPOIESIS IN PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA
by: V. E. Goldberg, et al.
Published: (2016-11-01)

Histomorphological evaluation of docetaxel effects on testes and epididymides in Wistar rats
by: Muntadher Salman Ashour, et al.
Published: (2025-03-01)

MECHANISMS OF ACTIVATION OF HEMATOPOIETIC RECOVERY DUE TO FILGASTRIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY WITH DOXORUBICIN/DOCETAXEL
by: Т. Yu. Khrichkova, et al.
Published: (2016-02-01)

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis
by: Ying Zhang, et al.
Published: (2025-01-01)

Results of combination treatment using docetaxel in an adjuvant chemotherapy regimen for resectable breast cancer
by: L. V. Bolotina, et al.
Published: (2014-07-01)

Montelukast reduced docetaxel-induced peripheral neuropathy in rats by altering oxidative stress, histopathological damage, and gene expressions
by: M.D. Karakoç, et al.
Published: (2025-05-01)

Pharmacokinetic and Pharmacodynamic Study of Folic Acid-Modified Chitosan–Stearic Acid Nanomicelles Loaded with Tetrandrine for Rheumatoid Arthritis
by: Shuai Ma, et al.
Published: (2025-01-01)

A multicenter retrospective study to evaluate safety and efficacy of tocopheryl polyethylene glycol succinate docetaxel in various cancers
by: Shirish S Alurkar, et al.
Published: (2020-01-01)

Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature
by: Tomoko Yoshimoto, et al.
Published: (2018-02-01)

Towards personalized prostate cancer treatment with docetaxel in indonesia: a pharmacogenomics perspective
by: Jekmal Malau, et al.
Published: (2025-04-01)

Clinical Presentations and Characteristics of NSAIDs Hypersensitivity in a Tertiary Care Hospital in Indonesia: A Case Series
by: Nurmesa A, et al.
Published: (2025-01-01)

ANTIMETASTATIC POTENTIAL OF CUCUMIN IN ANAPLASTIC THYROID CANCER AND COMBINED ACTIVITY WITH DOCETAXEL
by: Mehmet Ali Koçdor, et al.
Published: (2022-08-01)

Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim
by: Tomonori Makiguchi, et al.
Published: (2025-06-01)

Formation of Docetaxel-related Substances in the Polymer Particles During Storage and Gamma-treatment
by: Yu. I. Poltavets, et al.
Published: (2020-02-01)

Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis
by: Chengwen Sun, et al.
Published: (2025-07-01)

Synergistic Effects of Carvacrol and Thymol on Docetaxel-Induced Cytotoxicity in the A549 Cell Line by Evaluating Cell Viability and Oxidative Stress
by: Mohammad Shokrzadeh, et al.
Published: (2025-07-01)

Olmesartan Medoxomil Nanomicelle Using Soluplus for Dissolution Enhancement :Preparation, In-vitro and Ex-vivo Evaluation
by: Nawal Ayash Rajab, et al.
Published: (2025-06-01)

The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience
by: Qiyan Cai, et al.
Published: (2025-07-01)

Self‐reported accidental allergic reactions among patients with challenge‐verified food allergy
by: Sebastian Vigand Svendsen, et al.
Published: (2025-06-01)

Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons
by: Hui-Ai Zeng, et al.
Published: (2025-02-01)

N-glycosylation of ACTRIIB enhances protein stability leading to rapid cell proliferation and strong resistance to docetaxel in nasopharyngeal carcinoma
by: Qin Qin, et al.
Published: (2025-02-01)

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial
by: Qihua Zou, et al.
Published: (2025-05-01)

Docetaxel-loaded pH/ROS dual-responsive nanoparticles for the targeted treatment of gastric cancer
by: Junjia Wu, et al.
Published: (2025-02-01)